Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: A patent review

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 12, 2009, Pages 1675-1713

  Paone, Daniel V ^a   Staas, Donnette D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CGRP; CGRP antagonists; CGRP receptor; CGRP receptor antagonists; Migraine; Olcegepant; Telcagepant

Indexed keywords

4 OXOBUTYRAMIDE; AMIDE; AMIDINE; AZEPANE; BENZIMIDAZOLONE; BENZODIAZEPINE; BI 44370; BMS 694153; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN RECEPTOR LIKE RECEPTOR; CAPROLACTAM; CAPROLACTAM AZABENZIMIDAZOLONE; CARBAMIC ACID; GLYCINAMIDE; IMIDAZOLINONE; INDAZOLE DERIVATIVE; MK 2918; MK 3207; OLCEGEPANT; PLACEBO; PYRIDINOL; PYRIDONE DERIVATIVE; PYRIMIDINE; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; SPIROAZAOXINDOLE; SPIROCYCLOPENTANE PIPERAZINONE; SULFONYLIMIDAMIDE; TELCAGEPANT; TETRAHYDROAZEPINOINDAZOLE; UNCLASSIFIED DRUG; UREA; ZOLMITRIPTAN;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IC 50; MIGRAINE; NEUROBLASTOMA CELL; NONHUMAN; PATENT; RECEPTOR AFFINITY; REVIEW; SURFACE PROPERTY; UNSPECIFIED SIDE EFFECT;

ANIMALS; AZEPINES; DIPEPTIDES; DRUG DESIGN; DRUG INDUSTRY; HUMANS; IMIDAZOLES; MIGRAINE DISORDERS; PATENTS AS TOPIC; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 71449109620     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903359822     Document Type: Review

References (141)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-270
2. Durham PL. CGRP-receptor antagonists - a fresh approach to migraine therapy? N Engl J Med 2004;350: 1073-1075
3. Silberstein SD. Migraine. Lancet 2004;363:381-391
4. Poyner DR. Calcitonin gene-related peptide: multiple actions, multiple receptors. Pharmacol Ther 1992;56:23-51
5. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61
6. Olesen J, Diener H.-C, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-1110
7. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)- 2-oxo-1- (2,2,2-trifluoroethyl)azepan- 3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo [4,5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-5567
8. Edvinsson L. New therapeutic target in primary headaches - blocking the CGRP receptor. Expert Opin Ther Targets 2003;7:377-383 and references cited therein
9. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine attack. Ann Neurol 1990;28:183-187
10. Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008;155:967-969
11. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008;48:1259-1268
12. Conner AC, Hay DL, Howitt SG, et al. Interaction of calcitonin-gene- related peptide with its receptors. Biochem Soc Trans 2002;30:451-455
13. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54:233-246
14. Boehringer Ingelheim. Modified aminoacids, pharmaceuticals containing these compounds and method for their production. WO 98/11128; 1998.
15. Rudolf K, Eberlein W, Engel W, et al. Development of human calcitonin gene-Related Peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2- [3,5-Dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-L-lysyl]-4- (4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 2005;48:5921-5931
16. Doods H, Hallermayer G, Wu Dm, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-423
17. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002;277:14294-14298
18. Escott KJ, Beattie DT, Connor HE, et al. Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide. Brain Res 1995;669:93-99
19. Iovino M, Feifel U, Yong C-L, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-656
20. Boehringer Ingelheim. Selected CGRP antagonists, method for production and use thereof as medicament. WO2007028812; 2007.
21. Boehringer Ingelheim. Antagonists of calcitonin gene-related peptide. US 6313097; 2001.
22. Boehringer Ingelheim. Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions. US 2006/0079504; 2006.
23. Boehringer Ingelheim. CGRP antagonists. US 2007/0244099; 2007, continuation of US 2004/0132716; 2004 (abandoned)
24. Boehringer Ingelheim. Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7479488; 2009.
25. Boehringer Ingelheim. Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions. US7205294; 2007.
26. Boehringer Ingelheim. Selected CGRP antagonists method for production and use thereof as medicament. WO 2007/045672; 2007.
27. Boehringer Ingelheim. Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions. US 2008/ 0280887; 2008.
28. Boehringer Ingelheim. Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions. US 2007/0049581; 2007.
29. Boehringer Ingelheim. CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7528129; 2009.
30. Boehringer Ingelheim. DE102006039038; 2008
31. Boehringer Ingelheim. Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7491717; 2009.
32. Boehringer Ingelheim. Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7439237; 2008.
33. Boehringer Ingelheim. X = O: selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7279471; 2007; X = NH: selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US7547694; 2009.
34. Boehringer Ingelheim. Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions. US2007/0072847; 2007.
35. Boehringer Ingelheim. Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions. US2005/0250763; 2005.
36. Boehringer Ingelheim. Production method. US2008/045705; 2008.
37. Boehringer Ingelheim. Novel preparation process. WO2009/021942; 2009.
38. Boehringer Ingelheim. Novel compounds. WO2009/043797; 2009.
39. Boehringer Ingelheim Pharmaceuticals. BI 44370 TA in acute migraine attack. ClinicalTrials.gov identifier NCT00751803
40. Boehringer Ingelheim. (a) Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof. US7026312; 2006. (b) Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof. US7538115; 2009.
41. Boehringer Ingelheim. Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof. US6949541; 2005.
42. Boehringer Ingelheim. Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof. US7230001; 2007.
43. Boehringer Ingelheim. Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof. US7407963; 2008.
44. Boehringer Ingelheim. Novel compounds. WO2009/034028; 2009.
45. Boehringer Ingelheim. Novel compounds. WO2009/034029; 2009.
46. Boehringer Ingelheim. CGRP antagonists. WO2009/050232; 2009.
47. Boehringer Ingelheim. CGRP antagonists. WO2009/050234; 2009.
48. Boehringer Ingelheim. CGRP antagonists. WO2009/050235; 2009.
49. Boehringer Ingelheim. CGRP antagonists. WO2009/050237; 2009.
50. Boehringer Ingelheim. Novel compounds. WO2009/065919; 2009.
51. Boehringer Ingelheim. Novel compounds. WO2009/065920; 2009.
52. Boehringer Ingelheim. Novel compounds. WO2009/065922; 2009.
53. Boehringer Ingelheim. Novel compounds. WO2009/065921; 2009.
54. Williams TM, Stump CA, Nguyen DN, et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepine lead. Bioorg Med Chem Lett 2006;16:2595-2598
55. Merck and Co., IncBenzodiazepine CGRP receptor antagonists. US7196079; 2007
56. Merck and Co., Inc. CGRP receptor antagonists. WO2006/078554; 2006
57. Merck and Co., IncBenzodiazepine CGRP receptor antagonists. US7476665; 2009
58. Burgey CS, Stump CA, Nguyen DN, et al. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine. Bioorg Med Chem Lett 2006;16:5052-5056
59. Merck and Co., Inc. Heterocyclic benzodiazepine CGRP receptor antagonists. WO2007/016087; 2007
60. Shaw AS, Paone DV, Nguyen DN, et al. Caprolactams as potent CGRP receptor antagonists for the treatment of migraine. Bioorg Med Chem Lett 2007;17:4795-4798
61. Merck and Co., IncCGRP receptor antagonists. US7205292; 2007
62. Merck and Co., Inc. CGRP receptor antagonists. US7491,713; 2009
63. Merck and Co., Inc. CGRP receptor antagonists. US6953790; 2005. See also continuation patents (a) US7235545; 2007 (b) US7452903; 2008, and (c) US7534784; 2009
64. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 N-[(3R,6S)-6-(2,3- Difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-421
65. Hershey JC, Corcoran HA, Baskin EP, et al. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 2005;127:71-77
66. Merck and Co., Inc. CGRP receptor antagonists. WO2006/041830; 2006
67. Merck and Co., Inc. Benzazepine compounds as CGRP receptor antagonists. WO2008/085317; 2008
68. Merck and Co., Inc. CGRP receptor antagonists. WO2006/044449; 2006
69. Merck and Co., Inc. CGRP receptor antagonists. WO2006/047196; 2006
70. Merck and Co., Inc. CGRP receptor antagonists. WO2006/044504; 2006
71. Paone, D. V. Calcitonin gene-related peptide (CGRP) receptor antagonists for the treatment of migraine: development of orally bioavailable imidazoazepanes. Presented at the 235th American Chemical Society National Meeting, New Orleans, LA; April 2008;6
72. Merck and Co., Inc. CGRP receptor antagonists. WO2006/099268; 2006
73. Nguyen DN, Paone DV, Shaw AS, et al. Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template. Bioorg Med Chem Lett 2008;18:755-758
74. Merck and Co., IncCarboxamide spirohydantoin CGRP receptor antagonists. US7288559; 2007
75. Merck and Co., IncBenzodiazepine spirohydantoin CGRP receptor antagonists. US7205293; 2007
76. Merck and Co., IncAryl spirohydantoin CGRP receptor antagonists. US7189722; 2007
77. Merck and Co., IncMonocyclic anilide spirohydantoin CGRP receptor antagonists. US7192954; 2007
78. Merck and Co., Inc. Monocyclic anilide spirolactam CGRP receptor antagonists. WO2008/112159; 2008
79. Merck and Co., Inc. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate, and urea end groups. WO2008/127584; 2008
80. Merck and Co., IncBicyclic anilide spirohydantoin CGRP receptor antagonists. US7202251; 2007
81. Bell IM, Bednar RA, Fay JF, et al. Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett 2006;16:6165-6169
82. Merck and Co., Inc. Tricyclic anilide spirohydantoin CGRP receptor antagonists. WO2006/031676; 2006
83. Theberge CR, Bednar RA, Bell IM, et al. Potent benzimidazolone-based CGRP receptor antagonists. Bioorg Med Chem Lett 2008;18:6122-6125
84. Stump CA, Bell IM, Bednar RA, et al. The discovery of highly potent CGRP receptor antagonists. Bioorg Med Chem Lett 2009:19:214-217
85. Merck and Co., Inc. Bicyclic anilide spirolactam CGRP receptor antagonists. WO2006/031610; 2006
86. Merck and Co., Inc. Tricyclic anilide spirolactam CGRP receptor antagonists. WO2006/031491; 2006
87. Bell IM, Bednar RA, Corcoran HA, et al. The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett 2009;19:4740-4742
88. Merck and Co., Inc. Bicyclic anilide heterocyclic CGRP receptor antagonists. WO2008/130512; 2008
89. Merck and Co., Inc. Tricyclic anilide heterocyclic CGRP receptor antagonists. WO2008/153852; 2008
90. Merck and Co., Inc. Aryl spirolactam CGRP receptor antagonists. WO2006/031513; 2006
91. Merck and Co., Inc. Aryl heterocyclic CGRP receptor antagonists. WO2008/130524; 2008
92. Merck and Co., Inc. Monocyclic anilide spirolactam CGRP receptor antagonists. WO2006/029153; 2006
93. Merck and Co., Inc. Constrained spirocyclic compounds as CGRP receptor antagonists. WO2008/073251; 2008
94. Merck and Co., Inc. Substituted spirocyclic CGRP receptor antagonists. WO2008/020902; 2008
95. Bell IM. Discovery of a novel, orally bioavailable CGRP receptor antagonist for the treatment of migraine. Presented at the 237th American Chemical Society National Meeting, Salt Lake City, UT; March 2009;22
96. Merck and Co., IncCarboxamide spirolactam CGRP receptor antagonists. US7390798; 2008
97. Merck and Co., Inc. Carboxamide heterocyclic CGRP receptor antagonists. WO2008/153849; 2008
98. Merck and Co. , Inc. Bicyclic spirohydantoin CGRP receptor antagonists. WO2007/061695; 2007
99. Merck and Co., Inc. Spirohydantoin tricyclic CGRP receptor antagonists. WO2007/061694; 2007
100. Merck and Co., Inc. Spirolactam aryl CGRP receptor antagonists. WO2007/061677; 2007
101. Merck and Co., Inc. Spirolactam tricyclic CGRP receptor antagonists. WO2007/061692; 2007
102. Merck and Co., Inc. Spirohydantoin aryl CGRP receptor antagonists. WO2007/061676; 2007
103. Merck and Co., Inc. Spirolactam bicyclic CGRP receptor antagonists. WO2007/061696; 2007
104. Merck and Co., Inc. Hydroxypyridine CGRP receptor antagonists. WO2005/009962; 2005
105. Merck and Co., IncBenzimidazolinyl piperidines as CGRP ligands. US6552043; 2003
106. Bristol-Myers Squibb. Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists. US20050209256; 2005.
107. Bristol-Myers Squibb. Calcitonin gene related peptide receptor antagonists. WO03/104326; 2003.
108. Bristol-Myers Squibb. Heterocyclic anti-migraine agents. US2005/0153959; 2005.
109. Bristol-Myers Squibb. CGRP antagonists. US2007/0049577; 2007.
110. Bristol-Myers Squibb. US2007/0149502; 2007
111. Bristol-Myers Squibb. US2007/0149503; 2007
112. Bristol-Myers Squibb. Constrained compounds as CGRP-receptor antagonists. US7380930; 2008.
113. Bristol-Myers Squibb. Constrained compounds as CGRP-receptor antagonists. US7380931; 2008.
114. Bristol-Myers Squibb. Constrained compounds as CGRP-receptor antagonists. US7544680; 2009.
115. Bristol-Myers Squibb. Constrained compounds as CGRP-receptor antagonists. US7470679; 2008.
116. Bristol-Myers Squibb. Constrained compounds as CGRP-receptor antagonists. US7470680; 2008.
117. Bristol-Myers Squibb. (a) Anti-migraine treatments. US7314883; 2008.
118. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4-(8-Fluoro-2-oxo-1,2- dihydroquinazolin-3-(4H)-yl-N-(3- (7-methyl-1H-indazol-5-yl)-1-oxo- 1-(4-(piperidin-1-yl)piperidn-1-yl) propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008;51:4858-4861
119. Bristol-Myers Squibb. Novel therapeutic agents for the treatment of migraine. US2005/0215576; 2005.
120. Degnan AP, Conway CM, Dalterio RA, et al. Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability. Bioorg Med Chem Lett 2009;19:3555-3558
121. Bristol-Myers Squibb. Calcitonin gene related peptide receptor antagonists. US7220862; 2007.
122. Bristol-Myers Squibb. Calcitonin gene related peptide receptor antagonists. WO2005/065779; 2005.
123. SmithKline Beecham Corporation. Compounds and methods. WO97/09046; 1997.
124. Daines RA, Sham KKC, Taggart JJ, et al. Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett 1997;7:2673-2676
125. SmithKline Beecham Corporation. Compounds and methods. WO98/09630; 1998.
126. SmithKline Beecham Corporation. 4-Sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists. WO98/56779; 1998.
127. Aiyar N, Daines RA, Disa J, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 2001;296:768-775
128. Glaxo Group Limited. 5-Phenyl-1,3,4-oxadiazol-2-yl-acetyl- 4-piperidinyl derivatives as CGRP receptor antagonists. WO2009/000819; 2009.
129. Glaxo Group Limited. Pyrrolo[2,3-d] pyrimidine derivatives as CGRP receptor antagonists. WO2009/060682; 2009.
130. Vertex Pharmaceuticals Incorporated. CGRP receptor antagonists. WO2008/011190; 2008.
131. Vertex Pharmaceuticals Incorporated. CGRP receptor antagonists. WO2007/146349; 2007.
132. Neurogen Corporation. Biaryl ketone-substituted piperidines. WO2008/070014; 2008.
133. Neurogen Corporation. Amide-substituted aryl piperidines. WO2008/060568; 2008.
134. Grünenthal GmbH. Substituted cyclopentene compounds. US7109214;2006.
135. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-1312
136. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-2123
137. Doggrell SA. Telcagepant is a new oral treatment for migraine. Expert Opin Pharmacother 2009;10:1523-1526
138. Boehringer Ingelheim. Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine. US2006/0142273; 2006.
139. Boehringer Ingelheim. CGRP-antagonist in combination with serotonin-reuptake inhibitor for the treatment of migraine. US2005/0233980; 2005.
140. Boehringer Ingelheim. DE10314617; 2004
141. Rita Dobmeyer. Medication for the treatment or prevention of migraine. EP1374870; 2004.